From the Heart
to the Heart

Our Partners
About US

Welcome to
CellServe GmbH

Diseases of the heart are still the main cause of death in western industrial nations. In Germany, a total of about 50,000 people die each year from cardiac insufficiency. 

We use novel specialised cells from the patient’s heart biopsies to treat severe heart muscle weakness in a natural way and to improve the patient’s quality of life.

Our innovative cell therapy development focuses specifically on strengthening the heart muscle and the natural healing processes in the heart. 

Our Vision

Prolong life and improve the quality of life

To provide the first curative, alternative therapy (rather than just treating symptoms) with the goal to prolong life and improve the quality of life of patients with heart failure

OUR Mission

Affordable and less invasive

To market cardiac-derived cell therapy as an affordable and less invasive therapy than heart transplantation.

The Project

Explore our innovative project


Cardiac-derived Adherent Proliferating (CardAPcells): Proprietary novel cells derived from heart tissue for therapy of chronic myocardial insufficiency

Product strategy

A 2nd generation product cells brings immense upside potential and enables manufacturing of large quantities, thus improving scalability

How it works

CardAPcells are cultivated using the patients‘ own cells: Cells derived from heart tissue for the novel proprietary therapy of chronic myocardial tissue

Jasmin Nezirevic | Managing Partner
Prometheus Venture Advisors GmbH

Investor Relations

Contact us if you are interested and want to find out more about us


CellServe GmbH
Charitéplatz 1, internal: Virchowweg 11
10117 Berlin

Scroll to Top